OR WAIT 15 SECS
© 2020 MJH Life Sciences and BioPharm International. All rights reserved.
© 2020 MJH Life Sciences™ and BioPharm International. All rights reserved.
October 01, 2015
Rafe Swan/Getty Images; Dan WardIrreproducible preclinical research is a global, expensive, and well-recognized problem that contributes to delays a
The authors present the results of a survey of biologics manufacturers to evaluate how these manufacturers transfer analytical methods.
The author explores a dual-supplier sourcing strategy for single-use products and its ability to mitigate business continuity risk.
Surface plasmon resonance is helping define bispecific antibodies, the next-generation of biopharma therapeutics.
Dynamic light scattering techniques can monitor viruses and virus-like particles in their native state.
In the development of biopharmaceuticals and pharmaceuticals, the line is blurring.
Despite emergence of biologics, small-molecule APIs benefit from industry growth.
An approach to small-model generation and calibrating small-scale models to reliably predict performance at scale is presented.
Click the title above to open the BioPharm International October 2015 issue in an interactive PDF format.
September 01, 2015
China’s emergence as a significant commercial market is forcing manufacturers to re-evaluate their overall business model.